Voydeya Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber managing PNH patients, you may be fielding questions from patients who are struggling to access Voydeya (danicopan) despite having a valid prescription. This provider-focused guide explains the structural barriers that create access delays for Voydeya in 2026, clinical considerations for maintaining care continuity, and practical workflows to minimize the time between decision-to-prescribe and first dose.

The Clinical Context: Who Needs Voydeya?

Voydeya (danicopan) is indicated as add-on therapy to ravulizumab or eculizumab for adults with PNH who experience clinically significant extravascular hemolysis (EVH). Approximately 10–20% of PNH patients on C5 inhibitors develop clinically significant EVH — defined in the pivotal ALPHA trial as hemoglobin ≤9.5 g/dL with absolute reticulocyte count ≥120 × 10⁹/L, with or without transfusion support. These patients often present with persistent anemia, fatigue, and ongoing transfusion dependence despite what would otherwise appear to be adequate C5 inhibition.

Voydeya is a first-in-class oral complement Factor D inhibitor that selectively blocks the alternative complement pathway upstream of C3, reducing C3 opsonization and EVH. The ALPHA Phase 3 trial demonstrated significant improvements in hemoglobin at 12 weeks versus placebo, with many patients achieving transfusion avoidance. The drug is approved only as add-on — it has not demonstrated efficacy as monotherapy.

Why Patients Experience Access Delays: A Provider's View

Access barriers for Voydeya are structural and well-characterized. Understanding them allows you to anticipate and prevent delays:

1. VOYDEYA REMS: Prescriber, Pharmacy, and Patient Requirements

The VOYDEYA REMS program is the most significant structural access barrier. To prescribe Voydeya, you must:

Complete the prescriber REMS certification through the VOYDEYA REMS program (voydeyarems.com or 1-888-765-4747)

Ensure patients are vaccinated against Neisseria meningitidis (serogroups A, C, W, Y, B) and Streptococcus pneumoniae at least 2 weeks before first dose (per current ACIP recommendations for complement inhibitor recipients)

Counsel patients on the risk of serious encapsulated bacterial infections and provide a Patient Safety Card

Complete and submit the VOYDEYA Prescriber and Patient Enrollment Form to OneSource

Only Onco360 (and other REMS-certified pharmacies, per payer designation) can dispense Voydeya. Your prescription must be routed to Onco360 specifically. Note: some payers have designated CVS Specialty for dispensing — Onco360 is Alexion's contracted specialty pharmacy for OneSource patients.

2. Vaccine Timing: Build This Into Your Treatment Plan Early

The 2-week vaccination window is one of the most commonly underestimated timeline factors. If you determine a patient may be a Voydeya candidate, initiate vaccination counseling at that visit — even before PA submission — so that the required 2-week post-vaccination interval does not become a delay. If urgent therapy is required before vaccines can be administered, prescribe antibacterial prophylaxis as directed in the REMS prescribing information.

3. Prior Authorization: Required by All Payers, Often Complex

Given Voydeya's annual cost of $50,000–$100,000 as monotherapy cost (on top of ongoing C5 inhibitor costs), prior authorization is mandatory across essentially all payers. To maximize first-submission approval rates, ensure documentation includes:

PNH diagnosis confirmed by flow cytometry (ICD-10: D59.5)

Current C5 inhibitor (eculizumab or ravulizumab) with documentation of ≥6 months stable dosing

Recent labs demonstrating EVH: hemoglobin ≤9.5 g/dL and/or reticulocyte count ≥120 × 10⁹/L

Transfusion records (dates, units) if applicable within the prior 4–12 weeks

Vaccination status documentation (REMS compliance)

Letter of medical necessity addressing the specific payer's clinical criteria

Complete PA submissions are typically decided in 5–14 business days. Step therapy requirements vary by payer — most require documentation that patients have been on a C5 inhibitor for ≥6 months, which is consistent with Voydeya's approved add-on indication. If initially denied, request a peer-to-peer review with the payer's medical director; external appeal success rates for specialty rare disease drugs can exceed 50%.

Dosing Guidance: Starting Dose and Escalation

Voydeya is initiated at 150 mg three times daily (TID), with or without food. The dose may be increased to 200 mg TID if, after 4 weeks, the patient's hemoglobin has not increased by >2 g/dL, a transfusion was required in the prior 4 weeks, or clinical judgment indicates inadequate response. The 150 mg dose is achieved with one 50 mg tablet + one 100 mg tablet taken together TID; the 200 mg dose uses two 100 mg tablets TID (the 200 mg dose bottle configuration).

Monitor liver enzymes and lipids before and periodically during therapy. Voydeya is contraindicated in severe hepatic impairment (Child-Pugh C). Avoid concomitant rosuvastatin doses exceeding 10 mg/day; monitor closely if co-prescribing BCRP or P-gp substrates.

Leveraging Alexion Access Navigator for Provider Support

Alexion Access Navigator (alexionaccessnavigator.com) provides HCP-specific resources including: REMS enrollment guides, PA templates, letter of medical necessity templates, and Field Reimbursement Managers (FRMs) who can support your office during the access process. Enroll your office early and use these resources proactively. To learn more about helping patients find Voydeya in stock, see our guide at how to help patients find Voydeya in stock. For broader medication access support, medfinder for providers offers tools to verify specialty pharmacy availability on your patients' behalf.